- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell
loading systems, announces it will host a Lunch Briefing on January 22nd at the Phacilitate Cell and Gene Therapy Forum in Baltimore, Maryland with featured speaker Dan Gazit, PhD, DMD, Head of the Skeletal Biotech Laboratory, Director of the Hebrew University Center for Converging Sciences & Technologies, and Director of Stem Cell Therapeutics Research Lab, Department of Surgery and International Stem cell Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Dr. Gazit's presentation entitled "Genetically Engineered Stem Cells as a Platform for Skeletal Tissue Engineering" will discuss how genetically engineered mesenchymal stem cells are able to regenerate bone, cartilage, tendon, ligaments and intervertebral disk and how non-viral gene delivery works efficiently for mesenchymal stem cells.
Dr. Gazit is Professor and Head of the Skeletal Biotech Laboratory, Director of the Hebrew University Center for Converging Sciences & Technologies, Hebrew University, Jerusalem, Israel, and Director of Stem Cell Therapeutics Research Lab, Department of Surgery and International Stem cell Institute, Cedars-Sinai Medical Center, Los Angeles, CA. He received his academic training at the Hebrew University (DMD in Dental Medicine and PhD in bone biology) and joined the faculty of Dental Medicine in 1981 as a specialist in oral pathology. After a postdoctoral training in the University of California, San Francisco, he returned to the Hebrew University to become the head of the Skeletal Biotech Laboratory (1992-present), and Full Professor of Skeletal Biotechnology (2002-present). Dr. Gazit is world renowned for his work in musculoskeletal tissue engineering and orthopedic gene therapy. His scientific interests include adult stem cell biology, skeletal tissue engineering, gene therapy, non-invasive imaging, and nanotechnology. In these areas he has published
nearly 100 peer-reviewed papers and book chapters. He is especially interested in projects that bring together several scientific disciplines in order to advance stem cell-based therapeutic approaches in regenerative medicine.
For information on attending the lunch briefing, please contact MaxCyte.
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies.
MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.
For more information, visit http://www.maxcyte.com.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
For more information, please click here
22 Firstfield Road, Suite 250
Gaithersburg, MD 20878
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016
IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016
Cutting-edge nanotechnologies are breaking into industries November 18th, 2016